FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an oligonucleotide miR-132 miRNA inhibitor, a miR-132 miRNA inhibitor, a pharmaceutical composition for miR-132 inhibition, the use of an oligonucleotide, a miR-132 inhibitor or a pharmaceutical composition in the prevention or treatment of a disorder associated with, accompanied by and/or caused by abnormal expression of miR-132, in the prevention or treatment of cardiac disorders, in the prevention or treatment of contractile dysfunction, cardiac decompensation or heart failure, in the prevention or treatment of cardiac disorders, in the treatment or prevention of cardiac disorders as monotherapy or in combination with an additional drug, in the treatment or prevention of fibrotic disorders, in the treatment or prevention of cardiac fibrotic disorders, in the prevention or treatment of fibrotic disorders as monotherapy or in combination with an additional drug.
EFFECT: invention expands the arsenal of agents that inhibit miR-132 microRNA.
17 cl, 32 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF HEART FAILURE IN HUMANS | 2020 |
|
RU2811365C2 |
| DOUBLE TARGETING OF NUCLEOTIDE SEQUENCES MIR-208 AND MIR 499 IN TREATING CARDIAC DISEASES | 2010 |
|
RU2515926C2 |
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| THERAPEUTIC AGENT FOR THE TREATMENT OF CARDIOMYOPATHY, PREVIOUS MYOCARDIAL INFARCTION AND CHRONIC HEART FAILURE | 2018 |
|
RU2795320C2 |
| OLIGONUCLEOTIDE CONJUGATES | 2013 |
|
RU2653438C2 |
| LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES | 2014 |
|
RU2649367C2 |
| THERAPEUTIC USE OF INHIBITORS OF T-CELL ACTIVATION OR STIMULATION | 2016 |
|
RU2779308C2 |
| COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR | 2014 |
|
RU2668794C2 |
| METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS, DIRECTLY ACTING ON CONNECTIVE TISSUE GROWTH FACTOR (CTGF) | 2012 |
|
RU2608655C2 |
| MIR-155 INHIBITORS FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL) | 2016 |
|
RU2718534C2 |
